Transaction Overview 交易概览

•ArkBio announced an exclusive license agreement with Commave Therapeutics, an affiliate of Gurnet Point Capital, for the development, manufacture, and commercialization of AZSTARYS in Greater China.

•爱科百发宣布其子公司ArkBio从GPC旗下Commave公司引入一款用于治疗ADHD的首创新药AZSTARYS®，获得该资产在大中华区的独家开发、生产及商业化权利。

•Under the terms of the agreement, ArkBio will provides up to a total of $105.5 million USD in upfront, developmental and sale milestone, as well as tiered royalties on product net sales.

•该协议包含总金额1.055亿美元的预付款和开发销售里程碑付款，和年度销售额的提成。 

•YAFO Capital (Shanghai) acted as the exclusive financial advisor on this transaction for ArkBio.

雅法资本担任爱科百发买方顾问。

SHANGHAI, China, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”), an innovative biopharmaceutical company with a depth of expertise in pediatric drug development, today announced that Ark Biopharmaceutical Limited, a wholly-owned subsidiary of ArkBio, entered into an exclusive license agreement with Commave Therapeutics, SA (Commave), an affiliate of Gurnet Point Capital (GPC), a private investment firm focused on the life sciences and medical technology sectors. The license agreement provides for exclusive rights to develop, manufacture, and commercialize the first-in-class once-daily attention deficit hyperactivity disorder (ADHD) treatment AZSTARYS® (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) in Greater China, including mainland China, Hong Kong, Macau, and Taiwan.

上海, 2021年12月29日，(GLOBE NEWSWIRE) -- 爱科百发生物医药技术股份有限公司（“爱科百发”），一家专注于创新药物开发的生物医药企业于2021年12月28日宣布其子公司Ark Biopharmaceutical Limited与Gurnet Point Capital（GPC）旗下的Commave Therapeutics, SA（Commave）签订了独家许可协议，交易一款首创新药AZSTARYS®用于治疗ADHD。该协议授予爱科百发对AZSTARYS在大中华区的独家开发、生产及商业化权利。

Under the terms of the agreement, Commave will receive an upfront payment and is eligible to receive regulatory and sales milestone payments, totaling as much as $105.5 million USD, as well as tiered royalty payments based on aggregate annual net sales of AZSTARYS in Greater China.

根据协议条款，爱科百发支付给Commave包括预付款和开发销售的里程碑付款，总金额为1.055亿美元。此外还包括每年基于AZSTARYS在大中华区年度销售额的提成。

AZSTARYS, the first and only product containing SDX, an extended-release oral prodrug of d-MPH, was approved by the U.S. Food and Drug Administration (FDA) in March 2021 for the treatment of ADHD symptoms in patients aged 6 years and older. Corium, Inc., a wholly-owned portfolio company of GPC, is leading the U.S. commercialization efforts and launched AZSTARYS in the U.S. in July 2021.

AZSTARYS作为第一款有SDX缓释口服前药的产品，已于2021年3月获得美国食品药品监督管理局（FDA）批准、用于治疗6岁及以上ADHD患者。AZSTARYS已于2021年7月在美国上市，目前由GPC另一家子公司Corium负责在美国市场的商业化。

About ArkBio

ArkBio, an innovative biopharmaceutical company with a fully integrated platform addressing unmet medical needs in respiratory and lung diseases, by leveraging ArkBio’s RSV and anti-fibrotic franchises with first-in-disease or best-in-class drug potential, as well as pediatric drug development expertise.

爱科百发是一家拥有完整药物研发平台的创新生物制药公司，其丰富的儿科药物开发经验和集成了多款首创或同类最佳的呼吸道合胞病毒（RSV）和抗纤维化产品管线，将持续助力解决呼吸道和肺部疾病领域中未被满足的广阔医疗需求。

About YAFO Life Sciences

YAFO Life Sciences (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and MedTech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. For more information regarding YAFO, go to: www.yafocapital.com

雅法全球医疗（YAFO Life Sciences）是雅法资本旗下的医疗大健康部门。专注于帮助具有“中国角度”的海外医药企业在中国的授权、战略合作及融资；以及为中国创新药企业提供海外市场授权机会、海外市场咨询、寻找和引进海外标的服务。我们致力于成为全球医疗技术对接中国市场与资本的桥梁。目前海外有超过三十位资深合伙人，深度覆盖美国、欧洲、日本、韩国等全球医疗创新区域。

Contact

Wendi Xiang Vice President

wxiang@yafocapital.com

联系我们：相文迪 Vice President， wxiang@yafocapital.com